Apatinib (Rivoceranib) (Advenchen Laboratories, California), initially developed for human use and later adapted for canines, is a VEGFR2 inhibitor that showed similar effects in reducing tumor vascularization and growth in melanoma. This evidence concerns the gene KDR and melanoma.